Pletax, tablets 50 mg 30 pcs

Symptomatic treatment of intermittent claudication.

Indications

Symptomatic treatment of intermittent claudication.

Pharmacological effect

Pharmacodynamics

Special instructions

Before initiating cilostazol therapy, the possibility of prescribing other treatment options, such as surgical revascularization or conservative therapy, should be assessed.

Active ingredient

Cilostazol

Composition

Active ingredient:

Contraindications

Hypersensitivity to cilostazol or any other component of the drug;
Severe renal failure (creatinine clearance ≤25 ml/min);
Moderate or severe liver failure;
Chronic heart failure;
Predisposition to bleeding (for example, gastric or duodenal ulcer in the acute stage, recent [within the last 6 months] hemorrhagic stroke, proliferative diabetic retinopathy, poorly controlled hypertension);
Ventricular tachycardia, ventricular fibrillation or polytopic ventricular extrasystole in history (regardless of the presence or absence of adequate antiarrhythmic therapy);
Prolonged QT interval on ECG;
History of severe tachyarrhythmia;
Unstable angina or myocardial infarction within the last six months;
Invasive intervention on the coronary arteries within the last six months;
Concomitant use of two or more antiplatelet or anticoagulant drugs (for example, acetylsalicylic acid, clopidogrel, heparin, warfarin, acenocoumarol, dabigatran, rivaroxaban or apixaban);
Concomitant use of potent inhibitors of CYP3A4 or CYP2C19 (for example, cimetidine, diltiazem, erythromycin, ketoconazole, lansoprazole, omeprazole and HIV-1 protease inhibitors);
Pregnancy;
Breastfeeding period;
Age under 18 years (safety and effectiveness have not been studied).
With caution
Mild liver failure;
Chronic ischemic heart disease (in particular, stable angina pectoris);
Atrial or ventricular extrasystole, atrial fibrillation and flutter;
Diabetes mellitus;
Concomitant use of medications that lower blood pressure;
Simultaneous use of drugs that reduce blood clotting;
Concomitant use of CYPZA4 or CYP2C19 substrates (for example, cisapride, midazolam, nifedipine, verapamil);
Old age.

Side Effects

The most commonly reported side effects in clinical studies were headache (>30%), diarrhea and bowel movements (>15% each). These side effects were mild to moderate in intensity.
Adverse reactions by frequency of occurrence were classified as follows: very common (≥1/10), common (≥1/100 and <1/10), uncommon (≥1/1,000 and <1/100), rare (≥1/10,000 and <1/1000), very rare (<1/10,000), frequency unknown (cannot be determined based on available data).

Interaction

Acetylsalicylic acid

Overdose

Symptoms

Storage conditions

At a temperature not exceeding 30°C.
Keep out of the reach of children.

Shelf life

3 years.

Manufacturer

Oxford Laboratories Pvt. Ltd., India